论文部分内容阅读
目的 :分析先兆早产孕妇应用不同宫缩抑制剂治疗对产妇及围生儿结局影响,为先兆早产治疗药物的选择提供指导。方法 :选取我院2014年2月~2016年2月收治的38例先兆流产孕妇,按照随机数字表法分为利托君组、硫酸镁组,各19例,均给予常规保胎治疗,利托君组加用利托君静脉滴注,硫酸镁组加用硫酸镁静脉滴注;比较两组孕妇用药效果、分娩时间、围生儿结局及不良反应发生情况,探讨宫缩抑制剂的疗效与安全性。结果 :利托君组孕妇治疗效果均优于硫酸镁组,差异有统计学意义(P<0.05);利托君组1 min Apgar评分、新生儿窒息率优于硫酸镁组,差异有统计学意义(P<0.05)。硫酸镁组不良反应发生率高于利托君组,差异有统计学意义(P<0.05)。结论 :较硫酸镁而言,利托君治疗先兆早产具有更佳的疗效,对围生儿结局的改善具有积极意义,且安全性更佳,可作为先兆早产的首选治疗药物。
OBJECTIVE: To analyze the effects of different tocolytic agents on the maternal and perinatal outcomes in pregnant women with threatened preterm birth, and provide guidance for the selection of therapeutic agents for threatened premature delivery. Methods: Thirty-eight pregnant women with threatened abortion were selected from February 2014 to February 2016 in our hospital. According to the random number table, they were divided into two groups: Tuorun group with Ritoujun intravenous infusion of magnesium sulfate group plus magnesium sulfate intravenous infusion; comparison of the two groups of pregnant women medication effect, delivery time, perinatal outcome and adverse reactions, to explore the efficacy of tocolytic And safety. Results: The results of treatment of pregnant women in Ritonetan group were better than that of magnesium sulfate group (P <0.05), Apgar score of 1 min and the rate of neonatal asphyxia were better than those of magnesium sulfate group Significance (P <0.05). The incidence of adverse reactions in the magnesium sulfate group was higher than that in the ritodrine group, with significant difference (P <0.05). CONCLUSIONS: Compared with magnesium sulfate, Ritodrine is a more effective treatment for threatened preterm labor and has a positive effect on the improvement of perinatal outcome. It is also safe and can be used as the first choice of treatment for threatened preterm labor.